Unlock instant, AI-driven research and patent intelligence for your innovation.

TBAB humanized monoclonal antibody recombinant vector, recombinant antibody and preparation method of recombinant antibody

A technology for cloning antibodies and recombinant vectors, applied in the biological field, can solve the problems of poor stability and low yield of TBAB antibodies, achieve high antibody activity, broad application prospects, and meet the needs of scientific research and rapid detection

Pending Publication Date: 2020-09-22
成都和同易创生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the above-mentioned defects such as poor stability and low yield of TBAB antibody, the present invention provides a recombinant carrier of recombinant TBAB human monoclonal antibody, recombinant antibody and its preparation method, which can realize the mass production of antibody and help to improve the diagnosis of this disease. out rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TBAB humanized monoclonal antibody recombinant vector, recombinant antibody and preparation method of recombinant antibody
  • TBAB humanized monoclonal antibody recombinant vector, recombinant antibody and preparation method of recombinant antibody
  • TBAB humanized monoclonal antibody recombinant vector, recombinant antibody and preparation method of recombinant antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Construction of pCHO1.0-TBAB expression plasmid

[0030] Construction of stable expression cell lines.

[0031] Methods as below:

[0032] 1. Separation of plasma cells: collect blood from patients with Graves' disease, use density gradient centrifugation to separate plasma cells, extract RNA, and use RT-PCR to obtain cDNA.

[0033] 2. As shown in SEQ ID NO:1 and SEQ ID NO:2.

[0034] 3. Using specially designed upstream and downstream primers to PCR clone the heavy chain variable region (VH) and light chain variable region (VL) of the hybridoma cell.

[0035] Wherein the heavy chain (VH) primer sequence is shown in SEQ ID NO:3 and SEQ ID NO:4:

[0036] Upstream primer: 5' cctag caaatgcagctggtgcag3' (SEQ ID NO: 3);

[0037] Downstream primer: 5' gtatac tgaggagacggtgaccag 3' (SEQ ID NO: 4).

[0038] The light chain (VL) primer sequence is shown in SEQ ID NO:5 and SEQ ID NO:6::

[0039] Upstream primer: 5' gatatc ctgcctgtgctgactcag 3' (SEQ ID NO: 5);...

Embodiment 2

[0047] Example 2 pCHO1.0-TBAB expression plasmid was introduced into recipient cells to obtain recombinant antibody

[0048] The specific operation steps are as follows:

[0049] (1) co-transfect the eukaryotic expression cell line CHO with the expression vector connecting the heavy chain (VH) and light chain (VL) genes of the intended monoclonal antibody obtained in Example 1;

[0050] Wherein, in the step (1), the eukaryotic expression cell line CHO is a suspension culture, cultured with CD011 complete medium, and the culture condition is 37 ° C, 5% CO 2 , 120rpm; take CHO cells, count with trypan blue, the cell viability is above 98%, and use 0.5-1×10 6 / mL concentration inoculated cells in CD011 complete medium, 37°C, 120rmp, 5% CO 2 to cultivate.

[0051] (2) The day of inoculation is recorded as day 0, and the cell density is counted at about day 3 and day 4. If the cell density is greater than 4×10 6 / mL, add sodium butyrate (purchased from Sangon Bioengineering (Sh...

Embodiment 3

[0055] Example 3 Determination of recombinant antibody protein content

[0056] Every other day, 1 mL of the medium was taken, and the expression of antibody protein was determined by the BCA quantitative method.

[0057] Specific steps are as follows:

[0058] (1) Preparation of protein standards

[0059] a. Take 0.8mL of protein standard preparation solution and add it to a tube of protein standard (20mg BSA), fully dissolve and prepare a 25mg / mL protein standard solution. It can be used immediately after preparation, or can be stored at -20°C for a long time.

[0060] b. Take an appropriate amount of 25mg / mL protein standard and dilute it with culture medium to a final concentration of 0.5mg / mL.

[0061] (2) Preparation of BCA working solution

[0062] According to the number of samples, prepare 50 volumes of BCA reagent A plus 1 volume of BCA reagent B (50:1);

[0063] (3) Determination of protein concentration

[0064] a. Add 0, 1, 2, 4, 8, 12, 16, and 20 μL of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and particularly relates to a thyroid disease Graves' disease typing antibody TBAB humanized monoclonal antibody recombinant vector, a recombinant antibody and a preparation method of the recombinant antibody. Aiming at the defects of poor stability, low yield and the like of a TBAB antibody, the invention provides a recombinant vector of arecombinant TBAB humanized monoclonal antibody, the recombinant antibody and the preparation method of the recombinant antibody. When the recombinant antibody is prepared, a CHO expression system is adopted; stably expressed cell strains are constructed; the stable expression quantity is greater than or equal to 210 mg / L; meanwhile, the antibody is high in activity; the scientific research and detection requirements are completely met; localization of the typing antibody is achieved; the disease detection rate can be increased; and the application prospect is wide.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a TBAB human monoclonal antibody recombination carrier for thyroid disease Graves' disease typing antibody, a recombination antibody and a preparation method thereof. Background technique [0002] Autoimmune thyroid disorders (AITD) are a group of autoimmune diseases caused by the body's autoimmune reaction to thyroid tissue. It mainly consists of two diseases: Graves' disease (Graves' disease, GD) and Hashimoto's thyroiditis (Hashimoto's thyroiditis, HT). A common feature of AITD is the presence of a variety of autoantibodies against thyroid tissue in the serum of patients, including thyrotropin receptor antibody (TRAb), thyroglobulin antibody (TGAb), thyroid peroxidase antibody (TPOAb), etc. )Wait. In HT patients, the prevalence of TGAb is 25-50%, the prevalence of TPOAb is 90%, and the prevalence of TBAb (TSHR blocking autoantibodies), one of the TRAb classifications...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/85C12N15/13C12N5/10C07K16/28
CPCC07K16/28C12N15/85
Inventor 张涛刘江海杨菁
Owner 成都和同易创生物科技有限公司